宜明昂科-B（01541）今日盘中大涨5.17%，引发市场关注。这一涨幅很可能与公司昨日发布的2024年度业绩报告密切相关。
根据公告，宜明昂科-B 2024年实现营收约7414.9万元，同比大幅增长约191.1倍。这一惊人增长主要归因于公司与Axion Bio, Inc.达成的授权及合作协议，从中收取了首付款及近期付款。与此同时，公司持续加大研发投入，研发开支同比增加10.6%至3.23亿元，显示出公司对未来发展的信心。值得注意的是，尽管研发支出增加，公司2024年净亏损仍同比收窄16.76%至约3.16亿元。
分析人士认为，宜明昂科-B的业绩表现超出市场预期，尤其是营收的大幅增长和亏损的收窄，展现了公司业务模式的潜力和发展前景。这些积极因素可能是推动股价上涨的主要原因。投资者对公司未来的盈利能力和市场地位抱有更高期待，进而带动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.